Print

ZIOPHARM Oncology, Inc. (ZIOP.OB) Granted New U.S. Patent for Palifosfamide  
8/2/2012 10:18:59 AM

NEW YORK, Aug. 2, 2012 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) announced today that the United States Patent and Trademark Office issued Patent No. 8,232,262 entitled "Salts of Isophosphoramide Mustard and Analogs Thereof as Anti-Tumor Agents" with claims directed to pharmaceutical compositions, methods of treatment and methods of making a novel DNA cross-linker, including palifosfamide (ZIO-201). This newly issued patent provides subject matter exclusivity through 2027. The patent estate covering palifosfamide compositions, formulations, methods of use and methods of manufacture now includes issued patents in the United States, Australia, Europe, New Zealand and South Africa, as well as pending applications in the United States and various foreign jurisdictions.
//-->